Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q4 FY2026 Earnings Presentation
24 slides from Zim Laboratories's earnings presentation, May 2026
Slide 1: Earnings Presentation Q4 & FY26
ZiM ZIM LABORATORIES LIMITED Zeal & Innovation in Medicine EARNINGS PRESENTATION Q4 & FY26 Innovation Quality People www.zimlab.in
Slide 2: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited ("ZIM" or the "Company") solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 3: Content
CONTENT Q4 & FY26 Highlights 01 Financial performance snapshot for the quarter and full year Financial Performance Q4 & FY26 02 Revenue, EBITDA, margins and R&D investment trends Business Mix 03 Product and market mix driving the revenue profile R&D & Innovation 04 NIP & OTF pipeline progress, appro
Slide 4: Q4 & FY26 Financial Highlights
Q4Q4 & FY26 & FY26 Financial FINANCIAL Highlights HIGHLIGHTS ZiM ● FY26 (Full Year) ● Q4FY26 Full Year & Q4 Performance vs Prior Period FY26 vs FY25 Q4FY26 vs Q4FY25 Total Operating Income ₹3,744 Mn Total Operating Income ₹1,053 Mn ₹3,790 Mn ▼ 1.2% ₹1,087 Mn ▼ 3.2% EBITDA ₹414 Mn EBITDA ₹134 Mn ₹495
Slide 5: Regulatory Momentum (FY26)
REGULATORY MOMENTUM (FY26) Filings & Approvals · Pharmerging & RoW Markets FILED WITH MOH MAs RECEIVED FROM MOH NIP ODS FF NIP ODS FF 14 29 14 New Innovative Oral Thin Finished Form 5 New Innovative 25 Oral Thin 4 Finished Form Products Films Generic Products Films Generic 57 Total filings submitted
Slide 6: Strengthening Governance: Advisory Board
STRENGTHENING GOVERNANCE : ADVISORY BOARD 3 distinguished industry leaders — bringing deep expertise across Pharma, Finance and Global Markets 40+ yrs 35+ yrs 40+ yrs AV GS GB Mr. Annaswamy Vaidheesh Mr. Gautam Saigal Mr. Girdhar Balwani Chairman, Advisory Board Member, Advisory Board Member, Adviso
Slide 7: Strengthening Leadership and Organizational Capabilities
STRENGTHENING LEADERSHIP AND ORGANIZATIONAL CAPABILITIES Senior Management strengthened over the last 12 months (FY26) — 4 senior hires across International, Quality, HR & Procurement 26+ yrs 29+ yrs ~20 yrs 29+ yrs VB SR JP SC Mr. Vikrant Bendre Mr. Sridhar Reddy R Mr. Jitendra Pandey Mr. Srinivas
Slide 8: Status Update & Progress on CAPA Remediation
STATUS UPDATE & PROGRESS ON CAPA REMEDIATION Most of the CAPA remediation plan has been completed and implemented Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 DONE DONE IN PROGRESS IN PROGRESS Submission of CAPA Progress for upto Submission of CAPA Progress June / July EU GMP Inspection October 2026 Registration
Slide 9: Total Operating Income
TOTAL OPERATING INCOME Total Operating Income (Rs Mn) 3,790 3,744 1,087 1,053 887 718 Q1 FY 26 Q2 FY 26 Q3 FY 26 Q4 FY 26 FY 25 FY 26 o Total Operating Income at ₹3,744 Mn, tracked FY25; driven by increased contributions from our Innovative Product basket o Operating Income in Q4 and FY 2026 was adv
Slide 10: EBITDA & EBITDA Margin
EBITDA & EBITDA % EBITDA & EBITDA Margin 13.4% 495 13.1% 12.7% 414 11.1% EBITDA Margin 8.8% 7.9% Rs Mn 145 134 78 57 Q1 FY 26 Q2 FY 26 Q3 FY 26 Q4 FY 26 FY 25 FY 26 EBITDA EBITDA Margin o EBITDA at ₹414 Mn, down 16.4% YoY; EBITDA margins at 11.1% vs 13.1% in FY25 primarily due to lower Operating Inc
Slide 11: PAT & PAT Margin
PAT & PAT % PAT & PAT Margin 4.0% 122 3.6% 3.2% 1.6% 58 PAT Margin Rs Mn 44 37 -0.5% Q1 FY 26 Q2 FY 26 Q3 FY 26 Q4 FY 26 FY 25 FY 26 (4) (19) -2.6% PAT PAT Margin o PAT at ₹58 Mn in FY26 declined from ₹122 Mn in FY25 ; mainly due to flow through of lower EBITDA o Additionally, the capital expenditur
Slide 12: Pharmaceutical & Nutraceutical: Mix %
PHARMACEUTICAL & NUTRACEUTICAL : MIX % Pharma vs Nutra — Quarterly Revenue & Business Mix (Rs Mn) 954 754 87% 82% 82% 80% Revenue (Rs Mn) 78% Pharma Mix % 77% 75% 72% 71% 67% 2,836 2,990 196 300 141 268 224 155 266 157 891 786 911 654 739 732 552 560 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Q1 FY26 Q2 F
Slide 13: Innovative Product Contribution
INNOVATIVE PRODUCT CONTRIBUTION (NIP + OTF) Revenue (₹ Mn) & Contribution to Total Operating Income (%) 22% 21% 18% 186 16% 14% 14% 212 12% 13% 9% 438 6% 65 26 45 267 56 59 74 152 155 119 39 78 88 34 42 58 12 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 FY26 NIP ODS (%) of To
Slide 14: Business Mix
BUSINESS MIX Business Mix by Period 130 103 536 492 3,125 3,150 17 38 32 109 156 16 127 100 961 859 602 728 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 FY25 FY26 Export Domestic Deemed Export o Q4FY26: Export business share is at 82% of revenue in Q4FY26 with a decrease of 2.1% YoY o FY26: Export business at ₹3
Slide 15: Business Mix %
BUSINESS MIX % Business Mix % 2% 4% 2% 4% 3% 3% 10% 14% 14% 15% 14% 13% 88% 84% 82% 82% 82% 84% Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 FY25 FY26 Export Domestic Deemed Export 15
Slide 16: Region Wise Business Mix %
REGION WISE BUSINESS MIX % Region wise Business Mix (%) 5% 2% 2% 2% 4% 3% 18% 16% 9% 11% 24% 30% 35% 39% FY25 FY26 India Mena Asia (Ex. India) Africa Latam CIS Others o Asia (Ex. India) grew from 24% to 30% YoY - driven by formulation filings coming through in export markets o MENA Business declined
Slide 17: Advancing Innovation: NIP Product Pipeline (EU/UK)
ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK) 12 products in active development across 7 therapy areas — 3 regulatory approvals secured · Several products ready for filing Market Formulation Reg. Commercial Product Therapy Area Validation BE Studies Reg. Filing Review Dev. Approval Supplies Pr
Slide 18: Advancing Innovation: OTF Product Pipeline (EU/UK)
ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK) 5 OTF products across 3 therapy areas — 2 regulatory approvals secured · Sildenafil reaching Commercial Supplies Market Formulation Reg. Commercial Product Therapy Area Validation BE Studies Reg. Filing Review Dev. Approval Supplies Rizatriptan CNS
Slide 19: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D EXPENSE MIX & INVESTMENT AS % OF OPERATING INCOME 8.8% of OpInc 8.3% of OpInc Capital Expenses on BE Study & 101 2 85 31% 35% Registrations Capital Expenses on R&D Team Size PhDs Post-Graduates Infrastructure & Equipment 4% 1% R&D Expenses in P&L (Employee, Materia
Slide 20: Income Statement
INCOME STATEMENT Region wise Business Mix (%) Particulars (₹ Mn) Q4FY26 Q4FY25 YoY% Q3FY26 FY26 FY25 YoY% Total Operating Income 1,053 1,087 -3.2% 1,087 3,744 3,790 -1.2% Other Income 62 17 262.5% 17 114 58 96.3% Total Income 1,115 1,104 0.9% 1,104 3,858 3,848 0.2% EBITDA 134 163 -18.1% 145 414 495
Slide 21: Balance Sheet
BALANCE SHEET Region wise Business Mix (%) Particulars (₹ Mn) FY26 FY25 FY24 FY23 Gross Block – Tangible & Intangible Assets 3,862 3,453 3,089 2,257 including WIP Net Block – Tangible & Intangible Assets 2,573 2,347 2,031 1,357 including WIP Other Non- Current Assets 63 60 161 150 Current Assets 2,7
Slide 22: Key Financials
KEY FINANCIALS Gross & Net Fixed Assets (₹ Mn) Gross Current Assets (₹ Mn) & % of Total Assets 56% 3,862 3,453 3,089 2,347 2,573 51% 51% 2,257 2,031 1,357 49% FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Gross Fixed Assets Net Fixed Assets Net Worth (₹ Mn) Total Borrowing (₹ Mn) & Gearing % 2,961 45% 44%
Slide 23: Shareholding
SHAREHOLDING Ownership % (March 2026) · Traded Volume (In K) — BSE + NSE 26,593 5% 30% 26% 18,435 16,660 14,093 14,104 11,313 11,016 5,734 5,048 39% Promoter 30% Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Other Public 39% Body Corporates 26% NRI & Foreign 5% Shareholders: 16.6K a
Slide 24: Investor Relations & Contact
INVESTOR RELATIONS & CONTACT Zeal & Innovation in Medicine · ZiM Laboratories Limited · Nagpur, Maharashtra Mr. Zain Daud Ms. Sheetal Khanduja Address Zim Laboratories Limited Go India Advisors Sadoday Gyan (Ground Floor), Opposite NADT, Nelson Square, Nagpur, Maharashtra 440013 zain.daud@zimlab.in